3192 results for «810»
3192 results
Challenging Cases
10 Dec 2025 – From GulfPCR-GIM 2025
This session presents a series of challenging cardiology cases that span a spectrum of clinical scenarios, including innovative approaches to hypertrophic obstructive cardiomyopathy management, rare coronary artery anomalies, fibrous lesions, and unusual acute coronary syndromes. These case studies highlight diagnostic complexities and therapeutic strategies essential for...
Challenging cases from the East
10 Dec 2025 – From GulfPCR-GIM 2025
This session from Eastern cardiology centers addresses complex interventional challenges including recurrent left internal mammary artery (LIMA) failure, management of transcatheter aortic valve implantation (TAVI) complications, and treatment of heavily calcified coronary lesions. Through detailed case presentations and key learnings, it offers valuable insights into successful...
TAVI in small annulus - LIVE Case
11 Dec 2025 – From GulfPCR-GIM 2025
A 65-year-old female with obesity, diabetes mellitus, a history of stroke, atrial fibrillation, and RBBB on ECG, presented with symptomatic aortic stenosis and two-vessel coronary disease (OM and LAD, QFR: 0.70). Echocardiography and CT showed normal LV function (55%), a small annulus (370 mm²), and a...
Iatrogenic atrial septum defect closure: a necessary procedure?
18 Nov 2025 – From PCR London Valves 2025
This session addresses the clinical considerations surrounding iatrogenic atrial septal defects (ASDs) resulting from transseptal procedures. It covers prevention of residual defects, diagnostic evaluation, criteria for closure, procedural timing, and management strategies for related complications, supported by illustrative clinical cases demonstrating decision-making nuances.
TAVI complications - Part 5
18 Nov 2025 – From PCR London Valves 2025
This session highlights acute and urgent complications following TAVI implantation, including myocardial infarction, cardiac arrest, and challenging catheterization scenarios. It provides detailed case analyses illustrating the limits of TAVI procedures and the critical importance of prompt recognition and intervention in adverse events, enhancing clinician preparedness for...
Getting ready for tricuspid TEER: key steps in building a successful programme
14 Feb 2026 – From PCR Tokyo Valves 2026
Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.
Patient selection for tricuspid TEER in 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...
Alfieri's Bootcamp – Master TEER
A large Training Village awaits you at PCR London Valves 2018
Taming of the Hydra – percutaneous coronary intervention of a single coronary artery arising from the right sinus of Valsalva
20 Sep 2021
A single coronary artery arising from the right sinus of Valsalva with absent left main stem is an extremely rare coronary artery anomaly. Herein, a case of percutaneous coronary intervention (PCI) to a high grade proximal left anterior descending (LAD) stenosis of an anomalous single coronary...
Author
Mid-term echocardiographic outcomes following transapical mitral valve replacement: Updates from the Intrepid Pilot Study
19 Sep 2022
Pamela Gatto provides her take on the Intrepid Global Pilot Study which was presented by Renuka Jain at TCT Congress 2022.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
